skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Intravitreal bevacizumab treatment for retinal neovascularization and vitreous hemorrhage in proliferative diabetic retinopathy

(2951) Views  (1250) Full article downloads

Authors: Ashraf M El-Batarny

Published Date October 2007 Volume 2007:1(2) Pages 149 - 155
DOI: http://dx.doi.org/10.2147/OPTH.S

Ashraf M El-Batarny

Tanta University, Tanta, Egypt; Magrabi Eye and Ear Hospital, Muscat, Sultanate of Oman

Purpose: To report the short term anatomical and visual acuity response after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy.

Methods: Ten eyes having proliferative diabetic retinopathy were treated with at least one intravitreal injection of bevacizumab, 1.25 mg in 0.05 mL. Patients underwent complete ophthalmologic evaluation at baseline and follow up visits including Snellen’s best corrected visual acuity (BCVA), fundus biomicroscopy and fluorescein angiography. Vitreous hemorrhage precluding laser treatment was present in 6 eyes.

Results: Follow up ranged between 3 and 6 months (mean 4.2 ± 1.23 months). Improvement of vision was observed after one week with BCVA improved to 0.47 ± 0.26 compared with baseline BCVA of 0.365 ± 0.26 (P < 0.05). At last follow up, BCVA was 0.65 ± 0.33. Seven eyes had better visual acuity. Vitreous hemorrhage cleared completely in 4 eyes while 2 eyes had residual vitreous hemorrhage. Regression of retinal neovascularization was complete in 7 eyes, incomplete in 3 eyes. Regression was observed as early as 2 weeks after first injection. Reperfusion after regression was observed in 2 eyes. Patients received a mean of 1.7 ± 0.67 injections per eye. No complications were noted in all eyes. Pancryopexy was done in 1 eye and additional laser was done in 2 eyes.

Conclusion: Intravitreal bevacizumab was safe and effective in treatment of proliferative diabetic retinopathy. It can induce effective regression of retinal neovascularization and rapid clearance of vitreous hemorrhage. It can be used as an adjunctive therapy with laser photocoagulation and to enhance absorption of vitreous hemorrhage with subsequent deferral from vitrectomy.

Summary: Ten eyes having proliferative diabetic retinopathy were treated with intravitreal bevacizumab. Following injection, evident regression of retinal neovascularization and rapid clearance of vitreous hemorrhage as well as vision improvement was observed.

Keywords: intravitreal bevacizumab, proliferative diabetic retinopathy, retinal neovascularization, vascular endothelial growth factor, vitreous hemorrhage








Readers of this article also read:

Role of posaconazole in the management of oropharyngeal and esophageal candidiasis
The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation
Behavior and neuropsychiatric manifestations in Angelman syndrome
Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy
Smoking cessation: an economic analysis and review of varenicline
Disease-modifying therapies in relapsing–remitting multiple sclerosis
Antigenic epitopes prediction and MHC binder of a paralytic insecticidal toxin (ITX-1) of Tegenaria agrestis (hobo spider)
The relationship between cellular adhesion and surface roughness for polyurethane modified by microwave plasma radiation
Annual direct cost of dry eye in Japan
Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy